IL269637A - Preparations and methods for the treatment of synovial diseases - Google Patents

Preparations and methods for the treatment of synovial diseases

Info

Publication number
IL269637A
IL269637A IL26963719A IL26963719A IL269637A IL 269637 A IL269637 A IL 269637A IL 26963719 A IL26963719 A IL 26963719A IL 26963719 A IL26963719 A IL 26963719A IL 269637 A IL269637 A IL 269637A
Authority
IL
Israel
Prior art keywords
compositions
methods
treating synucleinopathies
synucleinopathies
treating
Prior art date
Application number
IL26963719A
Other languages
English (en)
Hebrew (he)
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of IL269637A publication Critical patent/IL269637A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL26963719A 2017-03-31 2019-09-25 Preparations and methods for the treatment of synovial diseases IL269637A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762479818P 2017-03-31 2017-03-31
US201762528790P 2017-07-05 2017-07-05
PCT/IB2018/052236 WO2018178950A1 (en) 2017-03-31 2018-03-30 Compositions and methods for treating synucleinopathies

Publications (1)

Publication Number Publication Date
IL269637A true IL269637A (en) 2019-11-28

Family

ID=62092178

Family Applications (1)

Application Number Title Priority Date Filing Date
IL26963719A IL269637A (en) 2017-03-31 2019-09-25 Preparations and methods for the treatment of synovial diseases

Country Status (13)

Country Link
US (1) US20200377579A1 (enExample)
EP (1) EP3630815A1 (enExample)
JP (1) JP2020512368A (enExample)
KR (1) KR20200026789A (enExample)
CN (1) CN110997715A (enExample)
AU (1) AU2018242626A1 (enExample)
BR (1) BR112019020335A2 (enExample)
CA (1) CA3058304A1 (enExample)
IL (1) IL269637A (enExample)
JO (1) JOP20190227A1 (enExample)
MA (1) MA48730A (enExample)
SG (1) SG11201908672WA (enExample)
WO (1) WO2018178950A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2370466E (pt) 2008-12-19 2015-09-21 Univ Zuerich Autoanticorpos humanos anti-alfa-sinucleína
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
CA3076313A1 (en) * 2017-09-28 2019-04-04 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
WO2020079113A1 (en) * 2018-10-19 2020-04-23 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
AU2020394842A1 (en) * 2019-12-04 2022-06-30 Ac Immune Sa Novel molecules for therapy and diagnosis
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
TW202227131A (zh) 2020-09-10 2022-07-16 愛爾蘭商普羅佘納生物科技有限公司 帕金森氏症之治療
EP4401770A2 (en) 2021-09-16 2024-07-24 H. Lundbeck A/S Compositions and methods for treating synucleinopathies
CN120882734A (zh) * 2023-02-06 2025-10-31 创新生物肽有限公司 用于治疗神经紊乱的肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
PT2370466E (pt) * 2008-12-19 2015-09-21 Univ Zuerich Autoanticorpos humanos anti-alfa-sinucleína
AU2012272790B2 (en) * 2011-06-23 2016-10-06 Biogen International Neuroscience Gmbh Anti-alpha synuclein binding molecules
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн

Also Published As

Publication number Publication date
MA48730A (fr) 2020-04-08
KR20200026789A (ko) 2020-03-11
AU2018242626A1 (en) 2019-10-10
WO2018178950A1 (en) 2018-10-04
JOP20190227A1 (ar) 2019-09-30
EP3630815A1 (en) 2020-04-08
CA3058304A1 (en) 2018-10-04
SG11201908672WA (en) 2019-10-30
CN110997715A (zh) 2020-04-10
US20200377579A1 (en) 2020-12-03
BR112019020335A2 (pt) 2020-04-28
JP2020512368A (ja) 2020-04-23

Similar Documents

Publication Publication Date Title
IL304820A (en) Preparations and methods for the treatment of cancer
IL269637A (en) Preparations and methods for the treatment of synovial diseases
IL269620A (en) Preparations and methods for the treatment of phenylketonuria
IL260257A (en) Preparations and methods for the treatment of hemoglobinopathies
GB2578539B (en) Compositions and methods for preventing or treating muscle conditions
IL269490B (en) Surface treatment methods and preparations for the same purpose
IL274837A (en) Methods and preparations for the treatment of cancer
IL250715A0 (en) Preparations and methods for the treatment of cultural disorders
PT4215527T (pt) Composições e métodos para tratar a degradação retinal
IL256523A (en) Compositions and methods for treating cancer
IL271256A (en) Preparations and methods for the treatment of teopathy
DK3658142T3 (en) Compositions and methods for treating galactosemia
ZA202001880B (en) Compositions and methods for treating brain injury
IL255638A (en) Compositions and methods for treating cancer
LT3691649T (lt) Žaizdų gydymo kompozicijos ir būdai
IL271758A (en) Statin preparations and methods for use in the treatment of synuclein pathologies
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
ZA201605109B (en) Compositions and methods for treating neutropenia
IL271923A (en) Methods and compositions for treating addictions
IL272782A (en) Preparations and methods for the treatment of cancer
HUE068710T2 (hu) NK1-antagonista kombináció és eljárás szinukleinopátia kezelésére
SG11201802292UA (en) Composition for treating pain
IL272945A (en) Local preparations and methods of treatment
ZA201802268B (en) Methods and compositions for preventing or treating cancer
IL281501A (en) Preparations and methods for the treatment of cellulite